These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33183969)

  • 1. Aromatase Inhibitor Symptom Management Practices: A Retrospective Study.
    Ernst A; Flynn KE; Weil EM; Crotty BH; Kamaraju S; Fergestrom N; Neuner J
    Clin Breast Cancer; 2021 Feb; 21(1):e38-e47. PubMed ID: 33183969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.
    Graetz I; McKillop CN; Stepanski E; Vidal GA; Anderson JN; Schwartzberg LS
    J Cancer Surviv; 2018 Aug; 12(4):431-440. PubMed ID: 29492753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
    Li H; Sereika SM; Marsland AL; Conley YP; Bender CM
    J Clin Nurs; 2019 Dec; 28(23-24):4560-4571. PubMed ID: 31469461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
    Hyder T; Marino CC; Ahmad S; Nasrazadani A; Brufsky AM
    Front Endocrinol (Lausanne); 2021; 12():713700. PubMed ID: 34385978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
    Roberts K; Rickett K; Greer R; Woodward N
    Crit Rev Oncol Hematol; 2017 Mar; 111():66-80. PubMed ID: 28259297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
    Henry NL; Azzouz F; Desta Z; Li L; Nguyen AT; Lemler S; Hayden J; Tarpinian K; Yakim E; Flockhart DA; Stearns V; Hayes DF; Storniolo AM
    J Clin Oncol; 2012 Mar; 30(9):936-42. PubMed ID: 22331951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation.
    Henry NL; Speth K; Lintermans A; Kidwell KM; Carlson R; Hayes DF; Neven P
    Clin Breast Cancer; 2017 Aug; 17(5):350-355.e4. PubMed ID: 28365336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
    Kidwell KM; Harte SE; Hayes DF; Storniolo AM; Carpenter J; Flockhart DA; Stearns V; Clauw DJ; Williams DA; Henry NL
    Cancer; 2014 Aug; 120(16):2403-11. PubMed ID: 24802413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.
    Schover LR; Baum GP; Fuson LA; Brewster A; Melhem-Bertrandt A
    J Sex Med; 2014 Dec; 11(12):3102-11. PubMed ID: 25141792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etiology, assessment, and management of aromatase inhibitor-related musculoskeletal symptoms.
    Park SH; Knobf MT; Sutton KM
    Clin J Oncol Nurs; 2012 Jun; 16(3):260-6. PubMed ID: 22641317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options.
    Lombard JM; Zdenkowski N; Wells K; Beckmore C; Reaby L; Forbes JF; Chirgwin J
    Support Care Cancer; 2016 May; 24(5):2139-2146. PubMed ID: 26556210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors.
    Brown JC; Mao JJ; Stricker C; Hwang WT; Tan KS; Schmitz KH
    Breast J; 2014; 20(1):22-8. PubMed ID: 24165356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitor associated arthralgia: the importance of oncology provider-patient communication about side effects and potential management through physical activity.
    Nyrop KA; Callahan LF; Rini C; Altpeter M; Hackney B; DePue A; Wilson A; Schechter A; Muss HB
    Support Care Cancer; 2016 Jun; 24(6):2643-50. PubMed ID: 26757739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
    Sheng JY; Blackford AL; Bardia A; Venkat R; Rosson G; Giles J; Hayes DF; Jeter SC; Zhang Z; Hayden J; Nguyen A; Storniolo AM; Tarpinian K; Henry NL; Stearns V
    Breast Cancer Res Treat; 2019 Aug; 176(3):617-624. PubMed ID: 31079282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
    Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
    Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
    Menas P; Merkel D; Hui W; Lawton J; Harper A; Carro G
    J Oncol Pharm Pract; 2012 Dec; 18(4):387-93. PubMed ID: 22277833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients.
    Crew KD; Capodice JL; Greenlee H; Apollo A; Jacobson JS; Raptis G; Blozie K; Sierra A; Hershman DL
    J Cancer Surviv; 2007 Dec; 1(4):283-91. PubMed ID: 18648963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
    Swenson KK; Nissen MJ; Henly SJ; Maybon L; Pupkes J; Zwicky K; Tsai ML; Shapiro AC
    Oncol Nurs Forum; 2013 Nov; 40(6):549-57. PubMed ID: 24161633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
    Campbell A; Heydarian R; Ochoa C; Dwivedi AK; Nahleh ZA
    Breast J; 2018 May; 24(3):260-268. PubMed ID: 29442401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.